These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23178378)

  • 1. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
    Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells.
    Zdzisińska B; Bojarska-Junak A; Walter-Croneck A; Kandefer-Szerszeń M
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):153-63. PubMed ID: 20157786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
    Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Mitsiades C; Chauhan D; Okawa Y; Munshi NC; Richardson PG; Anderson KC
    Leukemia; 2008 Oct; 22(10):1925-32. PubMed ID: 18596740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
    J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts.
    Persson E; Lerner UH
    J Cell Biochem; 2011 Dec; 112(12):3732-41. PubMed ID: 21815197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17beta-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro.
    Li Q; Yu K; Tian X; Kong F; You Y; Chen Z; Zou P
    Leuk Res; 2009 Sep; 33(9):1266-71. PubMed ID: 19167063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of calcitonin on osteoblast cell proliferation and OPG/RANKL expression: experiment with mouse osteoblasts].
    Tian QX; Huang GY; Zhou JL; Liu QH; DU XR
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1501-5. PubMed ID: 17785093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation.
    Yang L; Hai Y; Zhou JL
    Chin Med J (Engl); 2011 Jul; 124(13):2033-7. PubMed ID: 22088466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of the osteoclast in pathogenesis of multiple myeloma].
    Zhang JH; Fu JX; Zhang XH; Sun Y
    Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):323-6. PubMed ID: 17877161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane-bound receptor activator of NFκB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors.
    Singh PP; van der Kraan AG; Xu J; Gillespie MT; Quinn JM
    Biochem Biophys Res Commun; 2012 May; 422(1):48-53. PubMed ID: 22561018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
    Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
    Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of RANKL/OPG during bone remodeling in vivo.
    Tanaka H; Mine T; Ogasa H; Taguchi T; Liang CT
    Biochem Biophys Res Commun; 2011 Aug; 411(4):690-4. PubMed ID: 21771583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats.
    Mai QG; Zhang ZM; Xu S; Lu M; Zhou RP; Zhao L; Jia CH; Wen ZH; Jin DD; Bai XC
    J Cell Biochem; 2011 Oct; 112(10):2902-9. PubMed ID: 21618594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.